AstraZeneca

Healthcare

Created in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, AstraZeneca is a science-led global biopharmaceutical company focusing on oncology, rare diseases, and biopharmaceuticals.

View Official AstraZeneca Careers

Official AstraZeneca Careers Website

Quick Facts

Founded: 1999 (Astra 1913 / Zeneca 1993)
Merger Of: Astra AB & Zeneca Group
Headquarters: Cambridge, United Kingdom
Public Ticker: LSE: AZN / NASDAQ: AZN

About AstraZeneca

AstraZeneca was formed in 1999 through the merger of Swedish pharmaceutical company Astra AB (founded 1913) and British chemical & pharmaceutical firm Zeneca Group (spun off from ICI in 1993). Headquartered in Cambridge, UK, it operates major R&D hubs in Cambridge, Gothenburg (Sweden), and Gaithersburg (USA).

Generating over $45 billion in annual revenue, AstraZeneca focuses on three core therapy areas: Oncology (Tagrisso, Enhertu, Imfinzi, Calquence), Rare Diseases (Alexion division), and Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (Farxiga, Symbicort).

What AstraZeneca Does

Oncology

Targeted therapies, antibody-drug conjugates (ADCs), immuno-oncology, and DNA damage response medicines.

Rare Disease (Alexion)

Complement-mediated therapeutics targeting rare genetic and autoimmune conditions.

Cardiovascular, Renal & Metabolism

Treatments for heart failure, chronic kidney disease (Farxiga), and metabolic health.

Respiratory & Immunology

Inhaled therapies, biologics, and immunology treatments for asthma, COPD, and autoimmune diseases.

Career Areas

Types of professional roles found inside AstraZeneca.

R&D Oncology & Biopharmaceutical Research
Clinical Trial Operations & Medical Affairs
Bioprocess Engineering & Manufacturing
AI, Computational Biology & Data Science
Regulatory Affairs & Safety
Commercial Strategy & Market Access
Financial Planning & Control
People Operations & HR

AstraZeneca's History

1999
Astra & Zeneca Merge
Astra AB and Zeneca Group merge to create AstraZeneca.
2013
Cambridge Discovery Centre
Announces move of global headquarters and main strategic R&D centre to Cambridge, UK.
2020
Oxford Vaccine Partnership
Partners with Oxford University to manufacture and distribute Vaxzevria COVID-19 vaccine globally at cost.
2021
Alexion Pharmaceuticals Acquisition
Acquires Alexion Pharmaceuticals for $39 billion, establishing a dedicated rare disease business unit.
2023
Enhertu ADC Success
Co-developed HER2-directed antibody-drug conjugate Enhertu achieves major clinical breakthroughs in breast cancer.